Abdominal puncture was performed 39 times in two years to excrete ascites. At age 89, she underwent an emergency operation due to umbilical hernia strangulation; abdominal disseminated lesions were found during the laparotomy, and pathological immunostaining of the excised specimens showed same patterns with the collected cells in the pleural effusion. She became bedridden postoperatively and died at age 90.
tomy was approximately 17%. The overall survival in CDDP-PEM chemotherapy for unresectable MPM cases was about 12 months. The 5-year survival rate of trimodality therapy with induction chemotherapy, extrapleural peumonectomy and adjuvant radiation for n0 cases of MPM was reported 55%. Ten-year survival case without surgical therapy or systemic chemotherapy has not yet been reported. For MPM cases with IMIG stages 1-2, repeated thoracic puncture might be one of the preferred and feasible treatment options. Background and Aims: Abnormal epidermal growth factor receptor (EGFR) signalling is the major driver pathway in lung adenocarcinoma in Asia. Although first/second/third generation EGFR tyrosine kinase inhibitors (EGFR TKIs) have improved the prognoses in patients with activating EGFR-mutant lung adenocarcinoma, the acquired EGFR-TKI (Osimertinib) resistance was occurred due to the single point mutation in EGFR (C797S). However, there are no available targeting drugs to significantly suppress the EGFR with activating/T790M/C797S in cis (triplemutant) mediated EGFR-TKI resistance.
Methods:
The triple-mutant EGFR-expressing H1975 and BaF3 cells were incubated and treated with the Compound 1. After various treatments, cell proliferation or apoptotic proportion was evaluated by the CellTiter 96 Aqueous MTS assay or flow cytometry. The effects of Compound 1 on the EGFR activity and expression levels were evaluated by in vitro kinase assay and western blot, respectively. In preclinical studies, this
Compound 1 was validated in the murine xenograft model by these ectopic EGFR-expressing cells.
Results: In this study, we have identified the novel small molecule to overcome activating C797S/T790M mediated EGFR-TKI resistance after performed high throughput screening (HTS) assay. This compound 1 induced cell apoptosis and suppressed tumor growth in triple-mutant EGFR-expressing H1975 cell model, enabling the suppression rate were much higher than those in wild-type EGFR. Furthermore, the cytotoxicity of Compound 1 in BaF3 model was rescued by Il-3 addition. Overall, these results implies that Compound 1 may selectively and specifically target triple-mutant EGFR while harbouring less activity toward wild-type EGFR and others. 
